BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33178776)

  • 1. Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.
    Yuan X; Liu T; Xu D
    Ann Transl Med; 2020 Oct; 8(19):1244. PubMed ID: 33178776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
    Yuan X; Yuan H; Zhang N; Liu T; Xu D
    Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Liu T; Li S; Xia C; Xu D
    Front Immunol; 2022; 13():1071390. PubMed ID: 36713366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.
    Yuan X; Dai M; Xu D
    Cancer Lett; 2020 Nov; 493():1-9. PubMed ID: 32768523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation and Hypermethylation of GABPB1 Is Associated with Aggressive Thyroid Cancer Features.
    Xing X; Mu N; Yuan X; Wang N; Juhlin CC; Strååt K; Larsson C; Neo SY; Xu D
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutations in telomere biology.
    Heidenreich B; Kumar R
    Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
    Yuan X; Larsson C; Xu D
    Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
    Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
    Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase and Telomeres Biology in Thyroid Cancer.
    Donati B; Ciarrocchi A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
    Juhlin CC
    Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations in thyroid cancer.
    Liu R; Xing M
    Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
    Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
    Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
    Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
    Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
    Yuan X; Mu N; Wang N; Strååt K; Sofiadis A; Guo Y; Stenman A; Li K; Cheng G; Zhang L; Kong F; Ekblad L; Wennerberg J; Nilsson IL; Juhlin CC; Larsson C; Xu D
    Oncogene; 2019 Feb; 38(7):965-979. PubMed ID: 30181547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
    Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
    Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
    Jin A; Xu J; Wang Y
    Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.